Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma

JAMA - Journal of the American Medical Association

Volumn 312, Issue 23, 2014, Pages 2505-2507

  Abramson, Jeremy S ^a,b   Chung, Raymond T ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; GUANINE;

ANTIVIRAL RESISTANCE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LARGE CELL LYMPHOMA; LIVER FAILURE; NONHUMAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT DURATION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; BLOOD; FEMALE; IMMUNOLOGY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE;

EID: 84919363586     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.16095     Document Type: Editorial

References (22)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14):1486-1500.
2. YeoW, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299-307.
3. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742-1749.
4. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: ameta-analysis. J Clin Virol. 2013;57(3):209-214.
5. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22(5):1170-1180.
6. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106(4):1164-1174.
7. Lok AS, Liang RH, Chiu EK,Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology. 1991;100(1): 182-188.
8. YeoW, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4): 605-611.
9. Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer. 2013;49(16):3486-3496.
10. Hsu C, Tsou HH, Lin SJ, et al; Taiwan Cooperative Oncology Group. Chemotherapyinduced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59(6):2092-2100.
11. Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32(33):3736-3743.
12. Matsue K, Kimura S, Takanashi Y, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. 2010;116 (20):4769-4776.
13. Loomba R, Rowley A,Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148(7):519-528.
14. YeoW, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22(5):927-934.
15. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapyassociated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008; 47(3):844-853.
16. Chang TT, Gish RG, de Man R, et al; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001-1010.
17. Lai CL, Shouval D, Lok AS, et al; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10): 1011-1020.
18. Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. doi:10.1001/jama.2014.15704.
19. Cunningham D, Smith P, Mouncey P, et al R-CHOP14 vs R-CHOP21: results of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol. 2011;29(15):Abstract 8000.
20. Yuan Y, Iloeje UH, Hay J, Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm. 2008;14 (1):21-33.
21. Zöllner B, Petersen J, Schröter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet. 2001;357(9260):934-935.
22. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31(22):2765-2772.